By Chuck Holt. ORLANDO—A new analysis of the MRD cohort in the CAPTIVATE clinical trial evaluating ibrutinib fixed-duration therapy in combination with venetoclax was revealed at the 2019 ASH Annual Meeting (Abstract 35). New data from the phase II …
